West Pharmaceutical Services (WPS) Stock Overview
Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for WPS from our risk checks.
WPS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
West Pharmaceutical Services, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$297.08 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.14 |
| 1 Month Change | 5.00% |
| 3 Month Change | 10.04% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| WPS | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 3.5% | 2.4% | -0.2% |
| 1Y | n/a | 4.7% | 12.2% |
Return vs Industry: Insufficient data to determine how WPS performed against the Swiss Life Sciences industry.
Return vs Market: Insufficient data to determine how WPS performed against the Swiss Market.
Price Volatility
| WPS volatility | |
|---|---|
| WPS Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: WPS has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine WPS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,800 | Michel Lagarde | www.westpharma.com |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
West Pharmaceutical Services, Inc. Fundamentals Summary
| WPS fundamental statistics | |
|---|---|
| Market cap | CHF 20.96b |
| Earnings (TTM) | CHF 464.31m |
| Revenue (TTM) | CHF 2.73b |
Is WPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WPS income statement (TTM) | |
|---|---|
| Revenue | US$3.33b |
| Cost of Revenue | US$2.10b |
| Gross Profit | US$1.22b |
| Other Expenses | US$658.90m |
| Earnings | US$564.90m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.03 |
| Gross Margin | 36.79% |
| Net Profit Margin | 16.98% |
| Debt/Equity Ratio | 6.8% |
How did WPS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 15:38 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Curtis Moiles | BNP Paribas |